<DOC>
<DOCNO>EP-0614379</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Technetium-99m labeled peptides for imaging
</INVENTION-TITLE>
<CLASSIFICATIONS>C07K1400	C07K14775	C07B5900	C07K700	C07K14435	C07K1400	C07K706	A61K5108	C07F1300	C07B5900	C07F1300	A61K3800	A61K5100	A61K5100	A61K3800	C07K708	A61K5102	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07K	C07K	C07B	C07K	C07K	C07K	C07K	A61K	C07F	C07B	C07F	A61K	A61K	A61K	A61K	C07K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07K14	C07K14	C07B59	C07K7	C07K14	C07K14	C07K7	A61K51	C07F13	C07B59	C07F13	A61K38	A61K51	A61K51	A61K38	C07K7	A61K51	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to radiolabeled imaging of a mammalian body. The invention in particular provides for reagents labeled with technetium-99m for such imaging. The invention provides peptides which bind Tc-99m and which can be targeted to specific sites within a mammalian body.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
DIATIDE INC
</APPLICANT-NAME>
<APPLICANT-NAME>
DIATIDE, INC.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BUTTRAM SCOTT
</INVENTOR-NAME>
<INVENTOR-NAME>
DEAN RICHARD T
</INVENTOR-NAME>
<INVENTOR-NAME>
MCBRIDE WILLIAM
</INVENTOR-NAME>
<INVENTOR-NAME>
BUTTRAM, SCOTT
</INVENTOR-NAME>
<INVENTOR-NAME>
DEAN, RICHARD, T.
</INVENTOR-NAME>
<INVENTOR-NAME>
MCBRIDE, WILLIAM
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
This invention relates to radiodiagnostic reagents and peptides, and
methods for producing labeled radiodiagnostic agents. Specifically, the
invention relates to technetium-99m (Tc-99m) labeled reagents, methods and
kits for making such reagents, and methods for using such reagents. In
particular, the invention relates to Tc-99m labeled peptides comprised of
between 4 and 100 amino acid residues and covalently linked to a radioisotope
complexing group.The use of chelating agents for radiolabeling polypeptides is known in
the prior art.Byrne et al., U.S. Patent No. 4,434,151 describe homocysteine
thiolactone bifunctional chelating agents that can couple radionuclides to
terminal amino-containing compounds capable of localizing in an organ or
tissue to be imaged.Fritzberg, U.S. Patent No. 4,444,690 describes a series of technetiumchelating
agents based on 2,3-bis(mercaptoacetamido) propanoate.Gansow et al., U.S. Patent No. 4,472,509 teach methods of
manufacturing and purifying metal chelate-conjugated monoclonal antibodies.Byrne et al., U.S. Patent Nos. 4,571,430 and 4,575,556 describe novel
homocysteine thiolactone bifunctional chelating agents for chelating
radionuclides that can couple radionuclides to terminal amino-containing
compounds capable of localizing in an organ or tissue to be imaged.Nicolotti et al., U.S. Patent No. 4,861,869 describe bifunctional
coupling agents useful in forming conjugates with biological molecules such
as antibodies. This reference describes compounds such as S-benzoylmercaptoacetylglycylglycylglycine.European Patent Application No. 84109831.2 (EP-A-0 135 160) describes technetium 
chelating complexes of bisamido-bisthio-ligands and salts thereof, used
primarily as renal function monitoring agents.European Patent Application No. 86100360.6 (EP-A-0 188 256) describes dithiol,
diamino, or diamidocarboxylic acids or amine complexes useful for making
technetium imaging agents.European Patent Application No. 88104755.9 (EP-A-0 284 071) describes various S-protected
mercaptoacetylglycylglycine chelating groups bound to large proteins
such as antibodies.Albert et al., UK Patent Application No. 8927255.3 (GB-A-2 225 579) disclose
radioimaging using somatostatin derivatives such as octreotide labeled with
111In via a chelating group bound to the amino terminus.Flanagan et al., European Patent Application No. 90306428.5 (EP-A-0 403 243) disclose
Tc-99m labeling synthetic peptide fragments via a set of organic chelating
molecules.Albert et al., European Patent Application No. WO
</DESCRIPTION>
<CLAIMS>
A method for preparing a scintigraphic imaging agent comprising the step of
reacting technetium-99m and a reducing agent with a peptide for imaging

targeting sites within a mammalian body, said peptide having between 4 and
100 amino acids and being covalently linked to a technetium-99m complexing

group comprising a thiol moiety being in the reduced form and having the
structure:


A-CZ(B)-[C(R
1
R
2
)]
n
-X

wherein

A is H, HOOC, H
2
NOC, (peptide)-NHOC, (peptide)-OOC or R
4
;
B is H, SH, -NHR
3
, -N(R
3
)-(peptide), or R
4
;
X is H, SH, -NHR
3
, -N(R
3
)-(peptide), or R
4
;
Z is H or R
4
;
R
1
, R
2
, R
3
, and R
4
 are independently H or lower straight or branched
chain or cyclic alkyl;
n is 0, 1 or 2;

and

where B is -NHR
3
 or -N(R
3
)-(peptide), X is SH, and n is 1 or 2;
where X is -NHR
3
 or -N(R
3
)-(peptide), B is SH, and n is 1 or 2;
where B is H or R
4
, A is HOOC, H
2
NOC, (peptide)-NHOC or (peptide)-OOC,
X is SH, and n is 0 or 1;
where A is H or R
4
, then where B is SH, X is -NHR
3
 or -N(R
3
)-(peptide)

and

where X is SH, B is -NHR
3
 or -N(R
3
)-(peptide);
where X is H or R
4
, A is HOOC, H
2
NOC, (peptide)-NHOC or (peptide)-OOC
and B is SH;
where Z is methyl, X is methyl, A is HOOC, H
2
NOC, (peptide)-NHOC or
(peptide)-OOC, B is SH and n is 0;

wherein the technetium-99m complexing group contains a single thiol. 
The method of claim 1, wherein the reducing agent is selected from the group
consisting of a dithionite ion, a stannous ion, and a solid-phase reducing agent.
A method for preparing a scintigraphic imaging agent comprising the step of
reacting a preformed labile complex of technetium-99m and a transfer ligand

with the peptide as defined in claim 1.
The method of any of claims 1 through 3, wherein the peptide has a formula:

HS-CH
2
-CO-GGGRALVDTLKFVTQAEGAK.amide.
A method according to any of the claims 1 to 4, wherein the peptide is
synthesized by 
in vitro
 solid-phase chemical synthesis.
A method according to claim 5, wherein the peptide and the technetium-99m
complexing moiety of the scintigraphic imaging agent are covalently linked

during the 
in vitro
 solid-phase chemical synthesis.
A composition of matter comprising stannous ions and a peptide for imaging
targeting sites within a mammalian body, said peptide having between 4 and

100 amino acids and being covalently linked to a technetium-99m complexing
group comprising a thiol moiety being in the reduced form and having the

structure:

A-CZ(B)-[C(R
1
R
2
)]n-X

wherein

A is H, HOOC, H
2
NOC, (peptide)-NHOC, (peptide)-OOC or R
4
;
B is H, SH, -NHR
3
, -N(R
3
)-(peptide), or R
4
;
X is H, SH, -NHR
3
, -N(R
3
)-(peptide), or R
4
;
Z is H or R
4
;
R
1
, R
2
, R
3
, and R
4
 are independently H or lower straight or branched
chain or cyclic alkyl;
n is 0, 1 or 2;
 
and


where B is -NHR
3
 or -N(R
3
)-(peptide), X is SH, and n is 1 or 2;
where X is -NHR
3
 or -N(R
3
)-(peptide), B is SH, and n is 1 or 2;
where B is H or R
4
, A is HOOC, H
2
NOC, (peptide)-NHOC or (peptide)-OOC,
X is SH, and n is 0 or 1;
where A is H or R
4
, then where B is SH, X is -NHR
3
 or -N(R
3
)-(peptide)

and

where X is SH, B is -NHR
3
 or -N(R
3
)-(peptide);
where X is H or R
4
, A is HOOC, H
2
NOC, (peptide)-NHOC or (peptide)-OOC
and B is SH;
where Z is methyl, X is methyl, A is HOOC, H
2
NOC, (peptide)-NHOC or
(peptide)-OOC, B is SH and n is 0;

wherein the technetium-99m complexing group contains a single thiol.
A kit for preparing a radiopharmaceutical comprising a sealed vial containing a
predetermined quantity of the composition of claim 7. 
A scintigraphic imaging agent comprising a peptide for imaging targeting sites
within a mammalian body, said peptide having between 4 and 100 amino acids

and being covalently linked to a technetium-99m complexing group comprising
a thiol moiety having the structure:


A-CZ(B)-[C(R
1
R
2
)]
n
-X

wherein

A is H, HOOC, H
2
NOC, (peptide)-NHOC, (peptide)-OOC or R
4
;
B is H, SH, -NHR
3
, -N(R
3
)-(peptide), or R
4
;
X is H, SH, -NHR
3
, -N(R
3
)-(peptide), or R
4
;
Z is H or R
4
;
R
1
, R
2
, R
3
, and R
4
 are independently H or lower straight or branched
chain or cyclic alkyl;
n is 0, 1 or 2;

and

where B is -NHR
3
 or -N(R
3
)-(peptide), X is SH, and n is 1 or 2;
where X is -NHR
3
 or -N(R
3
)-(peptide), B is SH, and n is 1 or 2;
where B is H or R
4
, A is HOOC, H
2
NOC, (peptide)-NHOC or (peptide)-OOC,
X is SH, and n is 0 or 1;
where A is H or R
4
, then where B is SH, X is -NHR
3
 or -N(R
3
)-(peptide)

and

where X is SH, B is -NHR
3
 or -N(R
3
)-(peptide);
where X is H or R
4
, A is HOOC, H
2
NOC, (peptide)-NHOC or (peptide)-OOC
and B is SH;
where Z is methyl, X is methyl, A is HOOC, H
2
NOC, (peptide)-NHOC or
(peptide)-OOC, B is SH and n is 0;

wherein the technetium-99m complexing group contains a single thiol and is labeled
with technetium-99m;

with the proviso that when the technetium-99m complexing group is cysteine or a

cysteine linked to a peptide, then 

a) the peptide if having between 4 and 50 amino acids does not contain the
amino acid sequence LDV, or
b) the peptide if having between 4 and 100 amino acids does not contain the
amino acid sequence EPPT.
A composition of matter that comprises the scintigraphic imaging agent of
claim 9 and optionally a pharmaceutically acceptable carrier, for use in

imaging a target site within a mammalian body.
</CLAIMS>
</TEXT>
</DOC>
